Topotecan Episcleral Plaque for Treatment of Retinoblastoma
A Phase I Study of Sequestered Transscleral, Controlled-Release Topotecan Delivered From an Episcleral Reservoir in Retinoblastoma Eyes
Sponsor: Targeted Therapy Technologies, LLC
This PHASE1 trial investigates Retinoblastoma and is currently ongoing. Targeted Therapy Technologies, LLC leads this study, which shows 12 recorded versions since 2021 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
12 versions recorded-
May 2025 — Present [monthly]
Unknown PHASE1
Status: Active Not Recruiting → Unknown
-
Sep 2024 — May 2025 [monthly]
Active Not Recruiting PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE1
-
Nov 2023 — Jul 2024 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
May 2023 — Nov 2023 [monthly]
Recruiting PHASE1
▶ Show 7 earlier versions
-
Feb 2023 — May 2023 [monthly]
Recruiting PHASE1
-
Sep 2022 — Feb 2023 [monthly]
Recruiting PHASE1
-
Oct 2021 — Sep 2022 [monthly]
Recruiting PHASE1
-
Sep 2021 — Oct 2021 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Jan 2021 — Sep 2021 [monthly]
Not Yet Recruiting PHASE1
-
Apr 2020 — Jan 2021 [monthly]
Not Yet Recruiting PHASE1
-
Dec 2019 — Apr 2020 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Targeted Therapy Technologies, LLC
For direct contact, visit the study record on ClinicalTrials.gov .